Large Outflow of Money Witnessed in Illumina

Illumina (ILMN): The stock had negative money flow to the tune of ($3.43 million) on Wednesday, which shows that the traders are selling the stock on the price strength. The inflow of money on upticks was $18.2 million, whereas, the outflow of money on downticks was $21.63 million and the ratio between the two was 0.84. The block trade had a negative net money flow of ($0 million). On the other hand, downticks amounted to $0 million of the traded value, which shows distribution in the stock by traders. Illumina (ILMN) closed with marginal gains of 31 cents to end the day at $180.66, an increase of 0.17% over the previous days close. The stock recorded 0.74% for the week.


Shares of Illumina Inc. rose by 1.42% in the last five trading days and 6.2% for the last 4 weeks. Illumina Inc. is up 31.55% in the last 3-month period. Year-to-Date the stock performance stands at -5.72%.

Illumina (ILMN) : Zacks Investment Research ranks Illumina (ILMN) as 2, which is a Buy recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 10 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 15 research analysts is 2.55, which indicates as a Hold.

Illumina (NASDAQ:ILMN): The stock opened at $180.31 and touched an intraday high of $181.32 on Wednesday. During the day, the stock corrected to an intraday low of $178.55, however, the bulls stepped in and pushed the price higher to close in the green at $180.98 with a gain of 0.35% for the day. The total traded volume for the day was 662,283. The stock had closed at $180.35 in the previous trading session.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *